[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endovascular-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endovascular-surgery":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100650192","type-b-aortic-dissection-quality-control-platform-100650192",false,"NCT07745309","Type B Aortic Dissection Quality Control Platform","Construction of Type B Aortic Dissection Quality Control Platform and Risk Prediction Mechanism","Inclusion Criteria\n\n1. Aged between 18 and 80 years (inclusive);\n2. Definite diagnosis of Stanford type B aortic dissection confirmed by three-dimensional CTA reconstruction;\n3. Underwent TEVAR, including standalone TEVAR and hybrid procedures (only non-thoracotomy hybrid procedures);\n4. Patients and their families signed informed consent and agreed to complete the 2-year full follow-up.\n\nExclusion Criteria\n\n1. Presence of severe comorbidities or other diseases (e.g., severe chronic obstructive pulmonary disease, malignant tumors, dementia) or any physical condition that may affect patient compliance with this study;\n2. A previous history of thoracic aortic surgery (including TEVAR, hybrid surgery, and open surgery);\n3. Congenital aortic malformations;\n4. Requiring concurrent intervention for cardiac or aortic sinus root lesions, or cardiac diseases that would alter the postoperative medication regimen;\n5. Pregnant or breastfeeding women;\n6. Complicated with Stanford type A intramural hematoma, supra-aortic vessel occlusion, or refusal of relevant repair;\n7. A history of stroke or acute myocardial infarction within 30 days prior to surgery;\n8. Receipt of any major surgical or interventional procedures within 30 days prior to surgery;\n9. Scheduled to undergo any major elective surgical or interventional procedures within 30 days after index surgery;\n10. Participation in other ongoing drug or device trials with unmet primary study endpoints.","ALL","18 Years","80 Years",{"count":20,"type":21},2375,"ESTIMATED","24 Months","OBSERVATIONAL","This study aims to establish a multicenter, prospective, observational registry database for type B aortic dissection based on approximately 60 regional sentinel hospitals across China. It develops a digital intelligent management system, formulates quality control indicators and data collection standards for type B aortic dissection, and optimizes the data quality control and evaluation system to realize comprehensive evaluation covering the entire diagnosis and treatment process and long-term prognosis. Artificial intelligence algorithms are adopted to construct a risk prediction model for adverse events, and auxiliary decision-making software is developed to identify potential risks of adverse events in a timely manner and establish an early warning system, ultimately reducing the in-hospital complication and mortality rates.\n\nRelying on the National Quality Control Platform for Peripheral Vascular Intervention, this study further builds a national quality control platform for type B aortic dissection covering more than 5,000 hospitals nationwide by establishing a three-level quality control system. By integrating health administrative data, quality control data, electronic medical record data and clinical research data, a high-quality, multi-dimensional national quality control platform is constructed to support the sustainable development of quality control work. In addition, a clinical research collaboration network will be established to conduct in-depth evaluation of the national diagnosis and treatment patterns and outcomes of type B aortic dissection. Regular national training and assessment programs will be organized to improve the overall diagnosis and treatment capacity of medical institutions at all levels and reduce regional and institutional disparities in the quality of clinical care for the disease.",[26,27,28,29],"Endovascular Surgery","Medical Quality","Prognostic Early Warning","Stanford Type B Aortic Dissection","NOT_YET_RECRUITING","2026-08-03",{"date":33,"type":34},"2026-08-04","ACTUAL",{"date":36,"type":21},"2026-08",{"date":38,"type":21},"2029-08",{"name":40,"class":41},"Chang Shu","OTHER_GOV",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100637050","a-prospective-randomized-study-comparing-the-safety-of-percutaneous-and-open-brachial-access-in-the-endovascular-treatment-of-peripheral-arterial-lesion-100637050","NCT07573644","A Prospective Randomized Study Comparing the Safety of Percutaneous and Open Brachial Access in the Endovascular Treatment of Peripheral Arterial Lesion","BRAVO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Endovascular diagnostic or therapeutic procedure via the brachial approach compatible with a 5F to 7F introducer\n* Patient affiliated with a social security scheme\n\nExclusion Criteria:\n\n* Adult patient under legal guardianship or curatorship\n* Contraindication to endovascular treatment\n* History of brachial artery puncture within the past 1 month\n* History of open surgical approach at the elbow\n* Presence of a stent at the puncture site\n* Acute upper limb ischemia\n* Life expectancy of less than one month\n* Patient refusal to participate in the study\n* Allergy to aspirin or clopidogrel\n* Pregnant woman\n* Patients not speaking the French language, refusing or unable to comply with the follow-up proposed in the study\n* Requirement for another endovascular procedure or open surgery within 30 days following the BRAVO study procedure",{"count":50,"type":21},246,"INTERVENTIONAL",[53],"NA","Endovascular treatment tends to replace open surgery in the management of peripheral arterial disease. Access via the common femoral artery remains the primary approach for peripheral arterial interventions. Brachial artery access has emerged as a valid alternative when femoral access is not feasible. Brachial access can be achieved either percutaneously or through an open surgical approach at the elbow.\n\nA limited number of studies have reported complication rates associated with open and percutaneous brachial access in the treatment of peripheral arterial disease. These studies have shown higher complication rates for percutaneous access (ranging from 6% to 9%) compared with open brachial access (ranging from 1% to 2%). However, no direct comparison between the two approaches has been reported to date.\n\nThis study is the first to provide a direct, prospective, randomized comparison between open brachial access and percutaneous brachial access",[56,26,57],"Endovascular Treatments","Peripheral Arterial",[59,60,61],"peripheral arterial","endovascular treatments","endovascular surgery","2026-05-01",{"date":64,"type":34},"2026-05-07",{"date":66,"type":21},"2026-06-01",{"date":68,"type":21},"2028-06-30",{"name":70,"class":71},"University Hospital, Brest","OTHER",11]